Oral GLP-1 medicines in Ireland: Foundayo, Wegovy tablets and Rybelsus
Compare three GLP-1 tablets by active ingredient, authorised use and what is confirmed about Irish access.
Health / The Compound journalPhoto: Windshear, 2023 · Wikimedia Commons · CC BY-SA 4.0 · cropped · Illustrative image.
Rybelsus and Wegovy tablets both contain semaglutide. Foundayo contains orforglipron. All three target the GLP-1 receptor, but their indications, formulation and regulatory status differ. Here is what we could verify for readers in the Republic of Ireland as of 19 November 2026.
Which oral GLP-1 medicines are authorised?
| Tablet | Active ingredient | EU status and main adult use |
|---|---|---|
| Rybelsus | Semaglutide | Authorised for insufficiently controlled type 2 diabetes. |
| Wegovy tablets | Semaglutide | Authorised for weight management in eligible adults. The weekly Wegovy injection is a different formulation. |
| Foundayo | Orforglipron | EMA committee recommended authorisation for weight management and type 2 diabetes. We could not verify a final Commission decision. |
EMA Rybelsus · EMA Wegovy product information · EMA Foundayo assessment · EU authorisation register
The Science Behind the Drug
Semaglutide is a peptide, a chain of amino acids. It crosses the stomach lining poorly on its own. The tablets contain salcaprozate sodium (SNAC) to help semaglutide be absorbed in the stomach. Food reduces absorption, which explains the fasting instructions. Taking the medicine by injection bypasses this absorption step. EMA Wegovy product information, sections 4.2 and 5.2
Orforglipron is a small non-peptide molecule. Its US label allows the tablet with or without food. Both active ingredients reach the same receptor after absorption and affect appetite and how the body regulates blood glucose. EMA Foundayo mechanism overview · FDA Foundayo prescribing information
Did researchers compare the tablets directly?
Yes. The 52-week ACHIEVE-3 trial compared orforglipron with oral semaglutide in people with type 2 diabetes taking metformin. Both reduced HbA1c, a measure of average blood glucose. The corresponding orforglipron groups had larger reductions in that trial. The comparison used oral semaglutide diabetes doses and a diabetes population. It leaves the head-to-head comparison with the weight-management Wegovy tablet unanswered. ACHIEVE-3 phase 3 trial · EMA evidence summary
Can you get these tablets in Ireland?
Rybelsus has Irish-authorised presentations listed by the HPRA. The example listing below gives marketing availability as unknown, so confirm the exact presentation with a pharmacist. Wegovy tablets have EU authorisation. We could not verify a Republic of Ireland launch or HSE reimbursement for the tablet specifically. Foundayo has US and UK authorisations, with different indications in those jurisdictions. We could not verify an Irish launch or HSE reimbursement for it. HPRA Rybelsus listing · Wegovy EU product information · UK MHRA · US FDA
Nausea, vomiting and diarrhoea can occur with either active ingredient. Severe or persistent abdominal pain needs urgent medical assessment. Use the patient leaflet for the exact product you have and talk to your prescriber before switching strengths, brands or formulations. EMA Wegovy patient leaflet · FDA Foundayo patient guide
What other oral GLP-1 medicines are in development?
Aleniglipron is an investigational small-molecule GLP-1 tablet. Structure Therapeutics reported in November 2026 that its two phase 3 chronic weight management studies were enrolling. Trial enrolment describes the stage of research. Authorisation would require a separate regulatory decision. November 2026 company update filed with the SEC
- How orforglipron works and how semaglutide works
- Irish GLP-1 reimbursement and the medical card and side effects and when to seek help
- Costs of commonly used GLP-1 products in Ireland
What to compare when two boxes both say semaglutide
The ingredient name alone cannot answer what the medicine is authorised to treat. Check the brand, formulation and country of the product information. In particular, a daily oral semaglutide product and a weekly injection have different administration instructions and absorption. Instructions for one tablet presentation should not be used to convert another. See the semaglutide guide for the product comparison. EMA Wegovy information · EMA Rybelsus information
How to read a claim that one pill works better
Start with the people recruited, the outcome and what the trial actually compared. A diabetes study can compare HbA1c after a specified period in people taking metformin. A weight-management trial can compare weight outcomes in a different population, possibly against placebo. Putting the headline numbers side by side does not create a head-to-head trial. The comparison is most useful when you keep the outcome and the comparator attached to every number. ACHIEVE-3 trial
Finally, distinguish authorisation from access. An Irish prescriber and pharmacist can advise about a product’s suitability, availability and likely cost. Reimbursement is another question and can depend on the specific product and indication. HPRA medicines database · EU medicines register
Cover photograph shows Japanese Rybelsus blister packs, photographed in 2023. Photograph and cropped versions licensed under CC BY-SA 4.0.


